Download - Thank you for viewing this presentation
![Page 1: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/1.jpg)
Thank you for viewing this presentation.
We would like to remind you that this material is the property of the author.
It is provided to you by the ERS for your personal use only, as submitted by the
author.
2010 by the author
![Page 2: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/2.jpg)
2
MDR- and XDR-TB:prevention, treatment and control
J-P Zellweger
ERS/TB PAN NET ToT, Barcelona 2010
![Page 3: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/3.jpg)
3
Objectives• To familiarise with the new documents available on
MDR- and XDR-TB management and with the specific components of the Stop TB Strategy
• To analyse the main findings on drug resistance trends, improvement of laboratory services and treatment delivery process, and the actions undertaken to tackle MDR- and XDR- TB
• To identify priorities and proposed solutions to further prevent the emergence of drug resistance and improve the management of MDR- and XDR- TB
![Page 4: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/4.jpg)
4
Causes of DR
![Page 5: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/5.jpg)
5
Guidelines for the programmatic management of drug-resistant tuberculosis (1)
1 Background information on DR-TB2 Framework for effective control of DR-TB3 Political commitment and coordination 4 Definitions: case registration, bacteriology and treatment
outcomes5 Case-finding strategies 6 Laboratory aspects 7 Treatment strategies for MDR-TB and XDR-TB 8 Mono- and poly-resistant strains9 Treatment of DR-TB in special conditions and situations10 DR-TB and HIV infection 11 Initial evaluation, monitoring of treatment and management of
adverse effects
![Page 6: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/6.jpg)
6
Guidelines for the programmatic management of drug-resistant tuberculosis (2)
12 Treatment delivery and community-based DR-TB support 13 Management of patients with MDR-TB treatment failure14 Management of contacts of MDR-TB patients15 Drug resistance and infection control 16 Human resources: training and staffing17 Management of second-line antituberculosis drugs 18 Category IV recording and reporting system19 Managing DR-TN through patient-centered careANNEX 1 Drug information sheetsANNEX 2 Weight-based dosing of drugs for adultsANNEX 3 Suggestions for further readingANNEX 4 Legislation, human rights, and patient’s right in TB
care prevention and control ANNEX 5 Use of experimental drugs outside of clinical trials ANNEX 5 Methodology
![Page 7: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/7.jpg)
7
New STB strategy and Update on XDR epidemiology
![Page 8: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/8.jpg)
8
![Page 9: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/9.jpg)
9
![Page 10: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/10.jpg)
10
![Page 11: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/11.jpg)
11
![Page 12: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/12.jpg)
12
![Page 13: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/13.jpg)
13
![Page 14: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/14.jpg)
14
DOTS MDR-TB
FUNDING: Government Commitment (10$/ case)
> money
Up to 20,000 $/ caseDIAGNOSIS: SS microscopy, QA and safety measures
+C, DST, SRL, QA, infection control
TREATMENT: SCC,DOT, 6-8 months, no hospitalization
24 months, mandatory DOT & hospitalization in reference facilities
TB drugs only, no AE relevant toxicity, need special drugs + expertise
TREATMENT MONITORING: SS, standard outcome definitions
C, DST, special outcome definitons
![Page 15: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/15.jpg)
15
Who needs DST?
• Cat I, II failures, chronics• Failure anti-TB TX in the private sector• Contacts of DR-/MDR-TB• HCW at risk, prisoners, homeless, etc.• No SS/C conversion Month 2,3• Residence in very high DR-prevalence settings• Exposure to poor quality drugs• Previous treatment by poor programmes• Co-morbidities favouring rapid transit/ malabsorbtion• HIV+ • If available: for ALL TB patients!
![Page 16: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/16.jpg)
16
Algorithm for rapid DST testing
![Page 17: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/17.jpg)
17
DST testing in routine conditions
![Page 18: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/18.jpg)
18
![Page 19: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/19.jpg)
19
How to design a regimen for MDR-TB cases
![Page 20: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/20.jpg)
20
![Page 21: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/21.jpg)
21
![Page 22: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/22.jpg)
22
![Page 23: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/23.jpg)
23
![Page 24: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/24.jpg)
24
![Page 25: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/25.jpg)
25
![Page 26: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/26.jpg)
26
![Page 27: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/27.jpg)
27
![Page 28: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/28.jpg)
28
![Page 29: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/29.jpg)
29
![Page 30: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/30.jpg)
30
XDR= extensively drug-resistant TB
Definition
Resistance to at least rifampicin and isoniazid, in addition to any fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin.
![Page 31: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/31.jpg)
31
What was known
• Operational definition, proposed without solid evidence
• SRLs’ survey on XDR-TB isolates (“ a posteriori”, no outcomes)
• Anecdotal description of virtually untreatable TB patients
![Page 32: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/32.jpg)
32
What was not known on XDR?
• Is the risk of death/ probability of success different from that of MDR?
• Are their clinical characteristics different? in HIV-negative patients?
• Is their infectiousness different?• Has the XDR definition a clinical relevance?
Which is the role of susceptibility to first-line drugs different from HR?
![Page 33: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/33.jpg)
33
ERS and TBNET studies contributed to answer
• Time to SS and C conversion double than MDR-TB• Risk of death 5.5 times higher• Higher failure and default rates than MDR-TB• Lower success rate than MDR-TB• High proportion of adverse events due to 2°-line TB
drugs• XDR-TB definition has both clinical and operational
significance
Migliori GB et al, ERJ 2007Sotgiu et al, ERJ 2008
![Page 34: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/34.jpg)
34
Global Policy: MDR-TB and XDR-TB
1. Strengthen basic TB control, to prevent M/XDR-TB2. Scale-up programmatic management and care of
MDR-TB and XDR-TB 3. Strengthen laboratory services for adequate and
timely diagnosis of MDR-TB and XDR-TB4. Ensure availability of quality drugs and their
rational use5. Expand MDR-TB and XDR-TB surveillance 6. Introduce infection control, especially in high HIV
prevalence settings7. Mobilize urgently resources domestically and
internationally8. Promote research and development into new
diagnostics, drugs and vaccines
![Page 35: Thank you for viewing this presentation](https://reader035.vdocument.in/reader035/viewer/2022070408/56814417550346895db0b640/html5/thumbnails/35.jpg)
Conclusions• MDR/XDTR-TB is one of the major threats for
the future control of TB
• MDR/XDR-TB is basically a man-made problem
• The main issues are:– Stopping the source: control of all ERRORS which
sustain the creation of new cases– Accessing second-line drugs– Managing medical, human and economical
problems associated with the treatment
35